The Global Women’s Healthcare Market is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period (2019 - 2024). The growth of the market is primarily driven by factors such as the growing incidence of chronic health conditions among women, government initiatives to curb population growth, and growing demand for contraceptives to prevent unintended pregnancies. Moreover, the growing focus on RD by key players for the development of advanced products is also a major factor in driving market growth.

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136585329

Browse in-depth TOC on "Women's HealthCare Market"

127 – Tables

27 – Figures 

146 – Pages

The postmenopausal osteoporosis segment accounted for the largest share of the women’s healthcare market, by application, in 2019

Based on application, the market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, PCOS, and other applications. In 2018, the postmenopausal osteoporosis segment accounted for the largest market share during the forecast period. Factors such as the growing prevalence of postmenopausal osteoporosis, the focus of pharmaceutical players on providing effective drugs for postmenopausal osteoporosis, and the high risk of osteoporosis fractures supported the growth of this segment. Additionally, factors such as old age and obesity further add to the risk of osteoporosis in women. This segment is also expected to register the highest CAGR during the forecast period.

The Proila segment is expected to grow at the highest CAGR, by drug, during the forecast period.

Based on drug, the market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28). Prolia is the fastest-growing segment of the market. Also, Prolia accounted for the larger share of the market in 2018. The increasing demand for Prolia due to the high prevalence of postmenopausal osteoporosis among women is the major factor responsible for the growth of this market segment.

Get Sample Pages:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=136585329

North America accounted for the largest share of the women’s healthcare market in 2019.

The global women’s healthcare market is segmented into five major regions, namely, North America, Europe, APAC, Latin America, and the Middle East Africa. In 2018, North America (US and Canada) was the largest and the fastest-growing regional market for women’s healthcare. The major factors supporting market growth include the growing prevalence of PCOS and postmenopausal osteoporosis, increasing median age of first-time pregnancies, and increased healthcare spending in the US and Canada. Also, the high awareness and understanding regarding contraceptives among American women and the easy access to modern contraception as compared to developing countries propel the market growth in this region.

Key players in the women’s healthcare industry

The market is fragmented in nature, with a large number of players, including tier 1 and mid-tier companies competing for market shares. The prominent players in the global market include Bayer AG (Germany), Allergan (Dublin), Merck Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), and Apothecus Pharmaceutical (US).

Frequently Asked Questions (FAQ):

• How big is the Women's Health Care Market?
• What is the growth rate of Women's Health Care Market?
• Which drug holds the largest share of the women’s healthcare Market?
• Which is the major application segment in the global women’s healthcare market?
• Who are the key players operating in the global women’s healthcare market?
• Which geographical region is dominating the global women’s healthcare market?

Speak to Analyst:

https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=136585329

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: 1-888-600-6441

Email: [email protected]